Genelux Co. (NASDAQ:GNLX) Insider Sells $10,517.32 in Stock

Genelux Co. (NASDAQ:GNLXGet Free Report) insider Caroline Jewett sold 4,961 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $2.12, for a total transaction of $10,517.32. Following the completion of the transaction, the insider now owns 16,174 shares in the company, valued at $34,288.88. The sale was disclosed in a filing with the SEC, which is available through this link.

Genelux Stock Performance

NASDAQ GNLX opened at $2.49 on Thursday. The firm’s 50 day moving average price is $2.85 and its 200-day moving average price is $6.33. Genelux Co. has a 52-week low of $1.71 and a 52-week high of $35.15. The company has a market cap of $85.53 million, a PE ratio of -2.57 and a beta of -1.58.

Genelux (NASDAQ:GNLXGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.08). The firm had revenue of $0.01 million for the quarter. On average, analysts forecast that Genelux Co. will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genelux

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its stake in shares of Genelux by 216.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after purchasing an additional 2,021 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Genelux by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock valued at $87,000 after purchasing an additional 1,573 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock valued at $91,000 after purchasing an additional 966 shares in the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in shares of Genelux during the fourth quarter valued at approximately $100,000. Finally, SageView Advisory Group LLC purchased a new stake in Genelux during the first quarter valued at approximately $121,000. 37.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Genelux in a research note on Monday, May 13th. Benchmark dropped their target price on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating on the stock in a research note on Friday, May 31st.

Check Out Our Latest Research Report on GNLX

About Genelux

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Read More

Insider Buying and Selling by Quarter for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.